Michael Sassano was an early investor in the United States cannabis industry and now heads SOMAÍ Pharmaceuticals, a next-generation biotech company centred on the cultivation, manufacturing, and distribution of GMP-certified cannabinoid-containing pharmaceutical products throughout the European Union. SOMAÍ opened Europe’s largest cannabis manufacturing facility earlier this year in Lisbon, Portugal.
The Natural Halo reports on the latest industry news, research and thought leadership on cannabis, psilocybin, ibogaine and other psychedelic substances, and the reported benefits of using natural medicines.
The growing science and evidence-based research highlights the therapeutic potential of cannabis and psychoactive products to treat severe depression, PTSD, drug dependency, end-of-life care and various other disorders and addictions.
As many countries begin legalising the use of cannabis and psychoactive treatments, we are driving the agenda for safe cannabis and psychedelic therapies to become regulated, legalised and widely available treatments accepted fairly in society.